Oral controlled release dosage form

• US 9,468,633 B2
• Filed: 08/20/2012
• Issued: 10/18/2016
• Est. Priority Date: 12/09/2002
• Status: Expired due to Fees

• Current Assignee: Andrx Pharmaceuticals (NC), Inc. (Abbvie Incorporated)
• Original Assignee: Andrx Pharmaceuticals (NC), Inc. (Abbvie Incorporated)
• Inventors: Dixit, Manesh, Chen, Chih-Ming, Cheng, Xiu Xiu, Xie, Jianbo
• Primary Examiner(s): Javanmard, Sahar
• Application Number:
  US13/590,061
• Publication Number:
  US 20130022678A1
• Time in Patent Office: 1,520 Days
• US Class Current: 1/1
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 9/209 containing drug in at least two layers or in the core and in at least one outer layer
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system

Abstract

A dosage form that provides a controlled release solid dosage form for the oral administration of a central nervous system stimulant, preferably methylphenidate hydrochloride.

Claims

1. A controlled release methylphenidate tablet comprising:

(a) a compressed mixture comprising;

(i) methylphenidate or a pharmaceutically acceptable salt or isomer thereof;

(ii) 1 to about 50% of a water soluble binder that gels or swells in the presence of water selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl methylcellulose or mixtures of the foregoing;

(iii) a diluent; and

(iv) a lubricant; and

(b) a controlled release coating surrounding the compressed mixture comprising;

(i) about 5 to about 95 weight percent of the controlled release coating of an enteric polymer selected from the group consisting of zein, poly(methacrylic acid, methyl methacrylate) 1;

2, shellac or mixtures thereof;

(ii) a plasticizer selected from a group consisting of acetyltributyl citrate, triacetin, acetylated monoglyceride, coconut oil, poloxamer, acetyltriethyl citrate, glycerin, sorbitol, diethyl oxalate, diethylmalate, diethylfumerate, dibutylsuccinate, diethylmalonate, dioctylphthalate, dibutylphthalate, dibutyl sebacate, triethyl citrate, tributylcitrate, glyceroltributyrate, polyethylene glycol, propylene glycol and mixtures; and

(iii) optionally an antisticking agent; and

(c) an initial immediate dose of methylphenidate or pharmaceutically acceptable salt thereof;

an immediate release coating comprising methylphenidate or a pharmaceutically acceptable salt thereof wherein the immediate release coating provides

wherein the controlled release methylphenidate tablet exhibits the following dissolution profile when tested in a United States Pharmacopeia type 2 (paddle) apparatus at 50 rpms in 900 ml of phosphate buffer with a pH of 7.5 and at 37°

C.;

1-35% of the methylphenidate is released after 1 hour;

5-40% of the methylphenidate is released after 2 hours;

not less than 25% of the methylphenidate is released after 4 hours; and

not less than 70% of the methylphenidate is released after 10 hours; and

when administered to humans exhibits a maximum plasma concentration of about 3 to about 20 ng/ml;

an AUC_0-24 of about 30 to about 200 ng hr/ml and;

when administered to humans produces a plasma peak for the initial immediate dose (T_max1) between 1 and 5 hours, and a plasma peak for the compressed mixture (T_max2) between 4 and 12 hours.

2. The controlled release methylphenidate tablet as defined in claim 1 where the anti-sticking agent is selected from the group consisting of talc, glyceryl monostearates, calcium stearate, magnesium stearate, stearic acid, glyceryl behenate, and polyethylene glycol.

3. The controlled release methylphenidate tablet as defined in claim 2 wherein said anti-sticking agent is talc.

4. The controlled release methylphenidate tablet as defined in claim 1 that exhibits the following dissolution profile when tested in a United States Pharmacopeia type 2 (paddle) apparatus at 50 rpms in 900 ml of phosphate buffer with a pH of 7.5 and at 37°

C.;

1-30% of the methylphenidate is released after 1 hour;

not less than 30% of the methylphenidate is released after 4 hours; and

not less than 80% of the methylphenidate is release after 10 hours.

5. The controlled release methylphenidate tablet as defined in claim 1 that exhibits the following dissolution profile when tested in a United States Pharmacopeia type 2 (paddle) apparatus at 50 rpms in 900 ml of phosphate buffer with a pH of 7.5 and at 37°

C.;

5-30% of the methylphenidate is released after 1 hour;

10-35% of the methylphenidate is released after 2 hours;

not less than 30% of the methylphenidate is released after 4 hours; and

not less than 80% of the methylphenidate is release after 10 hours.

6. The controlled release methylphenidate tablet as defined in claim 1 wherein the controlled release coating comprises poly(methacrylic acid, methyl methacrylate) 1:

2.

7. A controlled release methylphenidate hydrochloride tablet comprising:

(a) a compressed mixture comprising;

(i) methylphenidate hydrochloride;

(ii) 1 to about 50% of a water soluble binder that gels or swells in the presence of water selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl methylcellulose or mixtures of the foregoing;

(iii) a diluent; and

(iv) a lubricant; and

(b) a controlled release coating surrounding the compressed mixture comprising;

(i) about 5 to about 95 weight percent of the controlled release coating of an enteric polymer selected from the group consisting of zein, poly(methacrylic acid, methyl methacrylate) 1;

2, shellac or mixtures thereof;

(ii) a plasticizer selected from a group consisting of acetyltributyl citrate, triacetin, acetylated monoglyceride, coconut oil, poloxamer, acetyltriethyl citrate, glycerin, sorbitol, diethyloxalate, diethylmalate, diethylfumerate, dibutylsuccinate, diethylmalonate, dioctylphthalate, dibutylphthalate, dibutylsebacate, triethyl citrate, tributylcitrate, glyceroltributyrate, polyethylene glycol, propylene glycol and mixtures; and

(iii) optionally an antisticking agent; and

(c) an initial immediate dose of methylphenidate hydrochloride

wherein the controlled release methylphenidate tablet exhibits the following dissolution profile when tested in a United States Pharmacopeia type 2 (paddle) apparatus at 50 rpms in 900 ml of phosphate buffer with a pH of 7.5 and at 37°

C.;

1-35% of the methylphenidate is released after 1 hour;

5-40% of the methylphenidate is released after 2 hours;

not less than 25% of the methylphenidate is released after 4 hours; and

not less than 70% of the methylphenidate is released after 10 hours; and

when administered to humans exhibits a maximum plasma concentration of about 3 to about 20 ng/ml;

an AUC_0-24 of about 30 to about 200 ng hr/ml and;

an immediate release coating comprising methylphenidate hydrochloride wherein the immediate release coating provides

when administered to humans produces a plasma peak for the initial immediate dose (T_max1) between 1 and 5 hours, and a plasma peak for the compressed mixture (T_max2) between 4 and 12 hours.

8. The controlled release methylphenidate hydrochloride tablet as defined in claim 7 wherein the controlled release coating comprises poly(methacrylic acid, methyl methacrylate) 1:

2.